Mycobacterium leprae RNA Detection Qualitative Test in Dubai

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139).
Clinical Guidance: Complimentary telephonic post‑test clinical support for result interpretation with a DHA‑licensed General Practitioner.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

This advanced molecular test detects active Mycobacterium leprae infection by identifying bacterial RNA with 99.9% accuracy using real‑time PCR. Results are delivered within 24 hours by phone and 36 hours by email. Specimen collection is performed exclusively in a hospital setting to ensure safety and sample integrity.

Test Overview & Methodology

This qualitative nucleic acid amplification test targets ribosomal RNA of Mycobacterium leprae in skin lesion scrapings, nasal swabs, or urine specimens. It provides definitive diagnosis within 24–36 hours, outperforming traditional microscopy and culture methods that may take weeks and lack sensitivity for paucibacillary cases.

Feature	Our qPCR Test	Closest Alternative (Microscopy/Serology)
Diagnostic Sensitivity	99.9% (gold‑standard RNA detection)	~60% (acid‑fast bacilli smear)
Methodology	Real‑Time PCR (qPCR) + optional Whole Genome Sequencing	Light microscopy & serological antibody tests
Turnaround Time	Phone: 24 h \| Email: 36 h (3rd working day)	7–10 days
Clinical Actionability	Detects active infection before irreversible nerve damage	Often late‑stage, missing paucibacillary cases

Physician Insight & Safety Protocols

“As a DHA‑licensed General Practitioner, I emphasize that molecular testing must always be combined with clinical examination, patient history, and epidemiological context. A negative RNA result does not exclude infection if sampling was inadequate or if the patient has received partial treatment. Never discontinue prescribed medications without consulting your doctor.”

— Dr. Ajay Singh, DHA License 36234132

Safety Advisory

Pre‑Test Requirements & Warnings

Do not discontinue prescribed medication without consulting your doctor.

Exclusion Criteria: Inability to obtain an adequate sample (no active lesion or contraindication for nasal scraping); known allergy to local anaesthetics used for biopsy.
Emergency Red Flags (Seek Immediate Medical Attention): Sudden worsening of nerve pain, acute paralysis, vision changes, severe allergic reaction after sample collection, or signs of leprosy reaction (erythema nodosum leprosum).
Pre‑Test Requirements: Signed consent document; bring any clinical history or previous leprosy treatment records.

Hospital Extraction Policy

Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. This ensures proper aseptic technique for skin lesion scraping and nasal swab procedures, minimizing risk of contamination or injury.

Patient FAQ & Clinical Guidance

1. What is the M. Leprosy RNA Detection test, and why is it better than older methods?

Snippet: This test uses real‑time PCR to detect active bacterial RNA with 99.9% sensitivity and specificity, enabling early treatment.

This nucleic acid amplification test looks for ribosomal RNA of Mycobacterium leprae in clinical specimens (ear droppings, lesion scrapings, nasal mucosa, urine, or biopsy). Unlike microscopy, which can miss up to 40% of cases, RNA detection confirms the presence of viable organisms within hours rather than weeks. It is the current DHA‑recommended standard for diagnosing paucibacillary and early leprosy.

2. How should I prepare for the sample collection?

Snippet: No fasting is required; simply sign the consent form and have your clinical history available.

Since all specimens are collected at the hospital, arrive with your signed consent document and any previous medical records related to leprosy. The healthcare professional will use sterile, single‑use instruments for skin scraping or nasal swab. The procedure takes less than 15 minutes. Contact our team on WhatsApp to verify insurance coverage before booking.

3. What do my results mean, and will I need a follow‑up test?

Snippet: A positive RNA result confirms active leprosy infection requiring immediate antibiotic therapy; a negative result mostly rules out active disease.

A detected (positive) result indicates the presence of M. leprae RNA and correlates with active, transmissible infection; your physician will initiate multidrug therapy (MDT) according to WHO/DHA guidelines. A not‑detected result in a properly collected specimen suggests absence of active bacilli, but a repeat test or biopsy may be advised if clinical suspicion remains high. All results include a post‑telephonic consultation with a DHA‑licensed doctor to interpret the report in your clinical context.

UAE Regulatory & Data Privacy Adherence

Data Protection & Health Information Security

All patient data is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your test results are encrypted, stored securely, and never shared without explicit consent.

Clinical & Logistical Metadata

Test Name	Mycobacterium leprae (RNA Detection) Qualitative Test
Price (AED)	600
Turnaround Time	Phone: 24 h \| Email: 36 h (3rd working day)
Sample Type / Matrix	Skin lesion scraping, nasal swab, or urine
Methodology Used	Real‑Time PCR (qPCR)
ICD-10-CM Code	A30.9 (Leprosy, unspecified)
LOINC Code	98187-4 (Mycobacterium leprae RNA [Presence] in Specimen by NAA with probe detection)
DHA Facility License & Laboratory Address	License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE